View in EDS HTML Full Text PDF Full Text

A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM).

Saved in:
Bibliographic Details
Title: A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM).
Authors: Nagarajan C; Department of Haematology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore., Jen WY; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore., Ooi M; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., De Mel S; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Soekojo C; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore., Yoon SS; Seoul National University Hospital, Seoul, South Korea., Tan M; Department of Haematology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore., Chen Y; Department of Haematology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore., Li X; Singapore Clinical Research Institute, Singapore, Singapore., Pokharkar Y; Singapore Clinical Research Institute, Singapore, Singapore., Tham SN; Department of Haematology, Singapore General Hospital, Singapore, Singapore., Hashim NSB; Department of Haematology, Singapore General Hospital, Singapore, Singapore., Awasthi N; Singapore Clinical Research Institute, Singapore, Singapore., Burkill SM; Singapore Clinical Research Institute, Singapore, Singapore., Durie B; Cedars-Sinai Medical Center, Los Angeles, USA., Chng WJ; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore. mdccwj@nus.edu.sg.; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. mdccwj@nus.edu.sg.
Source: Blood cancer journal [Blood Cancer J] 2025 Jun 17; Vol. 15 (1), pp. 109. Date of Electronic Publication: 2025 Jun 17.
Publication Type: Letter
Journal Info: Publisher: Nature Pub. Group Country of Publication: United States NLM ID: 101568469 Publication Model: Electronic Cited Medium: Internet ISSN: 2044-5385 (Electronic) Linking ISSN: 20445385 NLM ISO Abbreviation: Blood Cancer J Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 40527888
AccessLevel: 2
PubType: Editorial & Opinion
PubTypeId: editorialOpinion
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Nagarajan+C%22">Nagarajan C</searchLink>; Department of Haematology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Jen+WY%22">Jen WY</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.; Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Ooi+M%22">Ooi M</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22De+Mel+S%22">De Mel S</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Soekojo+C%22">Soekojo C</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Yoon+SS%22">Yoon SS</searchLink>; Seoul National University Hospital, Seoul, South Korea.<br /><searchLink fieldCode="AU" term="%22Tan+M%22">Tan M</searchLink>; Department of Haematology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Chen+Y%22">Chen Y</searchLink>; Department of Haematology, Singapore General Hospital, Singapore, Singapore.; Duke-NUS Medical School, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Li+X%22">Li X</searchLink>; Singapore Clinical Research Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Pokharkar+Y%22">Pokharkar Y</searchLink>; Singapore Clinical Research Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Tham+SN%22">Tham SN</searchLink>; Department of Haematology, Singapore General Hospital, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Hashim+NSB%22">Hashim NSB</searchLink>; Department of Haematology, Singapore General Hospital, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Awasthi+N%22">Awasthi N</searchLink>; Singapore Clinical Research Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Burkill+SM%22">Burkill SM</searchLink>; Singapore Clinical Research Institute, Singapore, Singapore.<br /><searchLink fieldCode="AU" term="%22Durie+B%22">Durie B</searchLink>; Cedars-Sinai Medical Center, Los Angeles, USA.<br /><searchLink fieldCode="AU" term="%22Chng+WJ%22">Chng WJ</searchLink>; Department of Haematology-Oncology, National University Cancer Institute, Singapore, Singapore. mdccwj@nus.edu.sg.; Cancer Science Institute of Singapore, National University of Singapore, Singapore, Singapore. mdccwj@nus.edu.sg.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568469%22">Blood cancer journal</searchLink> [Blood Cancer J] 2025 Jun 17; Vol. 15 (1), pp. 109. <i>Date of Electronic Publication: </i>2025 Jun 17.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Letter
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Nature+Pub%2E+Group%22">Nature Pub. Group </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>101568469 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2044-5385 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220445385%22">20445385 </searchLink><i>NLM ISO Abbreviation: </i>Blood Cancer J <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40527888
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1038/s41408-025-01296-8
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 109
    Titles:
      – TitleFull: A phase 2 study of Daratumumab with Thalidomide and dexamethasone in relapsed and/or Refractory Myeloma (RRMM).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Nagarajan C
      – PersonEntity:
          Name:
            NameFull: Jen WY
      – PersonEntity:
          Name:
            NameFull: Ooi M
      – PersonEntity:
          Name:
            NameFull: De Mel S
      – PersonEntity:
          Name:
            NameFull: Soekojo C
      – PersonEntity:
          Name:
            NameFull: Yoon SS
      – PersonEntity:
          Name:
            NameFull: Tan M
      – PersonEntity:
          Name:
            NameFull: Chen Y
      – PersonEntity:
          Name:
            NameFull: Li X
      – PersonEntity:
          Name:
            NameFull: Pokharkar Y
      – PersonEntity:
          Name:
            NameFull: Tham SN
      – PersonEntity:
          Name:
            NameFull: Hashim NSB
      – PersonEntity:
          Name:
            NameFull: Awasthi N
      – PersonEntity:
          Name:
            NameFull: Burkill SM
      – PersonEntity:
          Name:
            NameFull: Durie B
      – PersonEntity:
          Name:
            NameFull: Chng WJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 17
              M: 06
              Text: 2025 Jun 17
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 2044-5385
          Numbering:
            – Type: volume
              Value: 15
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Blood cancer journal
              Type: main
ResultId 1